Cell Cycle · 2010 · 28 citations · 38 references
MedicineCancer BiologyOncologyCell DivisionMolecular OncologySignal TransductionCancer Cell SignalingCell Cycle SignalingCell-cycle DysregulationOncogenic Signaling PathwaysProtein Kinase CascadesSignal Transduction In CancerAcute Myeloid Leukemia BiologyCell Cycle InhibitionCell Division ControlMammalian Target Of Rapamycin SignalingMtor InhibitionMtor SignalingPolo-like Kinase FunctionPolo-like Kinase Inhibition
Polo like kinase-1 is a key effector of cell division and its overexpression in several cancers is often linked with negative prognostic. We recently described that Plk1 is overexpressed in acute myeloid leukemia, and that its inhibition selectively reduces the proliferation of leukemic cells. Here, we report that Plk1 inhibition or depletion using pharmacological and siRNA approaches decreased the phosphorylation of two mTOR substrates in AML cells. In HCT116 cells, inducible expression of a constitutively active form of Plk1 leads to activation of mTOR, as shown by increased phosphorylation of its 4E-BP1 and RPS6 down-stream targets. In addition, cells overexpressing the active form of Plk1 were characterized by abnormal growth that could be reversed by rapamycin, a specific inhibitor of the TORC1 complex. Altogether these data suggest the existence of a molecular and functional link between the Plk1 mitotic kinase and the mTOR pathway. Given the different established functions of Plk1 and mTOR during the cell cycle, we will discuss the possible meaning of this functional relationship.
38
Diane C. Fingar, Celeste Richardson, Andrew R. Tee et al. · Molecular and Cellular Biology · 2003 · 873 citations · Full text
BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo
Martin Steegmaier, Matthias Hoffmann, Anke Baum et al. · Current Biology · 2007 · 849 citations · Full text
Medicine, Oncology, Pharmacology +14